中京電子(002579.SZ):香港中揚累計減持782萬股 擬繼續減持不超1%股份
格隆匯 7 月 6日丨中京電子(002579.SZ)公佈,公司於近日日收到持股5%以上股東香港中揚電子科技有限公司(“香港中揚”)的告知函,告知其已減持情況及未來股份減持的計劃。因自身經營發展的資金需求,香港中揚已於2020年2月24日、2020年2月26日、2020年7月2日、2020年7月3日、2020年7月6日分別通過大宗交易的方式減持公司股份105萬股、56萬股、115萬股、475萬股、31萬股,合計減持782萬股,佔公司總股本的1.97%。
此外,自公告披露之日起15個交易日之後的6個月內,香港中揚擬通過集中競價減持股份數量不超過396.71萬股,不超過公司總股本的1%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.